全文获取类型
收费全文 | 22454篇 |
免费 | 1851篇 |
国内免费 | 623篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 321篇 |
妇产科学 | 193篇 |
基础医学 | 1610篇 |
口腔科学 | 167篇 |
临床医学 | 1930篇 |
内科学 | 5172篇 |
皮肤病学 | 313篇 |
神经病学 | 1149篇 |
特种医学 | 583篇 |
外国民族医学 | 1篇 |
外科学 | 2479篇 |
综合类 | 1668篇 |
现状与发展 | 2篇 |
预防医学 | 659篇 |
眼科学 | 242篇 |
药学 | 5405篇 |
10篇 | |
中国医学 | 317篇 |
肿瘤学 | 2602篇 |
出版年
2024年 | 30篇 |
2023年 | 518篇 |
2022年 | 631篇 |
2021年 | 1100篇 |
2020年 | 1041篇 |
2019年 | 941篇 |
2018年 | 841篇 |
2017年 | 940篇 |
2016年 | 857篇 |
2015年 | 959篇 |
2014年 | 1291篇 |
2013年 | 2519篇 |
2012年 | 1170篇 |
2011年 | 1337篇 |
2010年 | 1018篇 |
2009年 | 1026篇 |
2008年 | 998篇 |
2007年 | 949篇 |
2006年 | 877篇 |
2005年 | 713篇 |
2004年 | 572篇 |
2003年 | 563篇 |
2002年 | 508篇 |
2001年 | 394篇 |
2000年 | 330篇 |
1999年 | 278篇 |
1998年 | 272篇 |
1997年 | 260篇 |
1996年 | 209篇 |
1995年 | 198篇 |
1994年 | 162篇 |
1993年 | 159篇 |
1992年 | 120篇 |
1991年 | 108篇 |
1990年 | 100篇 |
1989年 | 92篇 |
1988年 | 77篇 |
1987年 | 94篇 |
1986年 | 64篇 |
1985年 | 85篇 |
1984年 | 81篇 |
1983年 | 57篇 |
1982年 | 80篇 |
1981年 | 57篇 |
1980年 | 57篇 |
1979年 | 45篇 |
1978年 | 44篇 |
1977年 | 28篇 |
1976年 | 28篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 77 毫秒
11.
Alexandra Katsimardou Konstantinos Imprialos Konstantinos Stavropoulos Alexandros Sachinidis Michalis Doumas 《Expert opinion on pharmacotherapy》2020,21(10):1241-1252
ABSTRACT
Introduction
Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications. 相似文献12.
13.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance. 相似文献
14.
15.
Ramya Deepthi Vinnakota Allan S. Brett 《The American journal of the medical sciences》2019,357(2):160-163
Iron deficiency anemia is often listed among potential adverse effects of gastric acid-suppressive medications, given that gastric acidity promotes intestinal absorption of nonheme iron. Additionally, the antacid calcium carbonate can inhibit iron absorption. However, there is little direct clinical evidence that proton-pump inhibitors, histamine-2 receptor antagonists, or calcium carbonate cause iron deficiency anemia. Most case reports have had substantial limitations (e.g., minimal follow-up and presence of other causes of iron deficiency), and retrospective cohort studies have lacked sufficient patient-specific detail to make strong causal inferences. We present 2 cases—both with detailed, prospective 10-year follow-up—in which combinations of proton-pump inhibitors, histamine-2 receptor antagonists and calcium carbonate were clearly associated with development of iron deficiency anemia. Overt iron-deficiency anemia is probably uncommon in patients who use acid-modifying medications and who have no other conditions that predispose to iron deficiency. Nevertheless, clinicians should be aware of this potential complication, given widespread use of these agents. 相似文献
16.
17.
《The Journal for Nurse Practitioners》2022,18(8):910-914
This is a case study of a 73-year-old woman recently diagnosed with Alzheimer disease living in an assisted living facility who presented to an outpatient behavioral health clinic with her son for evaluation and treatment of depression. This article highlights the presentation of depression (a diagnosis) versus apathy (a symptom of Alzheimer disease) and the need to assess for co-occurring mood disorders that warrant pharmacologic intervention as well as treatment for cognitive decline in Alzheimer disease. 相似文献
18.
19.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(7):415-421
Myelofibrosis (MF) is a BCR-ABL1− myeloproliferative neoplasm that arises from hematopoietic stem and progenitor cells frequently harboring a somatic driver mutation in 1 of 3 genes: JAK2, CALR, or MPL. The pathologic features of this hematologic malignancy include myeloproliferation, diffuse bone marrow fibrosis, and overactivation of the JAK-STAT pathway, resulting in enhanced inflammatory cytokine release. The common clinical manifestations of MF include systemic symptoms, abnormal peripheral blood count levels, and splenomegaly. However, it has become increasingly appreciated that significant clinical heterogeneity exists among patients with MF. Two distinct MF clinical phenotypes include the myeloproliferative and myelodepletive phenotype, with peripheral blood counts being the main discerning feature. Patients with the myeloproliferative phenotype will present with elevated peripheral blood counts and often experience significant constitutional symptoms and progressive splenomegaly. In contrast, patients with the myelodepletive phenotype will have low peripheral blood counts and will frequently require transfusion support. Current frontline therapies for MF, include ruxolitinib and fedratinib, which can exacerbate cytopenias and thereby pose an impediment to effective treatment of the myelodepletive patient. The present review discusses the clinical and prognostic implications of the myelodepletive phenotype and the therapeutic options and limitations for this subset of patients, representing an unmet clinical need. 相似文献
20.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献